Our study expounded the anti-renal cancer activity and mechanism of RAC at the molecular level; however, it is not sufficient for the clinical treatment and further research will be conducted in animals to provide a theoretical and experimental basis for further study and clinical treatment of RCC. Here, AKT1 is linked to renal cell carcinoma.